Literature DB >> 15008841

The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus.

L Flores1, M Vidal, J Abian, A Cases, J Ma Campistol, J Clària, S Lario, E Esmatjes.   

Abstract

BACKGROUND: Oxidative stress and transforming growth factor-beta 1 (TGF-beta1) are associated with diabetic complications, and smoking is a risk factor. AIMS: This study aimed (i) to compare urinary 8-epi-PGF2alpha and plasma and urinary TGF-beta1 levels obtained in heavy smokers with Type 1 diabetes with those observed in age-matched non-smoker patients with Type 1 diabetes and controls, and (ii) to investigate the effects of smoking cessation (SC) on the above-mentioned parameters in patients with Type 1 diabetes. METHODS AND
RESULTS: Compared with control subjects (n = 12), non-smoker diabetic patients (n = 12) presented higher values of urinary 8-epi-PGF2alpha (74.2 +/- 29.6 vs. 29.6 +/- 11.1 pg/mg urinary creatinine, P = 0.01), plasma TGF-beta1 (7.7 +/- 4.7 vs. 3.6 +/- 1.7 ng/ml, P = 0.001) and urinary TGF-beta1 (15.3 +/- 6.3 vs. 8.1 +/- 4.4 ng/mg urinary creatinine, P = 0.02). Compared with non-smoker diabetic patients, smoker diabetic patients (n = 16) showed higher levels of urinary 8-epi-PGF2alpha (107.8 +/- 40.2 vs. 74.2 +/- 29.6 pg/mg urinary creatinine, P = 0.0001), plasma TGF-beta1 (12.6 +/- 4.9 vs. 7.7 +/- 4.7 ng/ml, P = 0.001) and urinary TGF-beta1 (27.5 +/- 16.0 vs. 15.3 +/- 6.3 ng/mg urinary creatinine, P = 0.01). Smoker patients were included in a smoking cessation programme. In the 10 patients that gave up smoking there was a reduction of urinary 8-epi-PGF2alpha (basal: 110.47 +/- 47.0 vs. week 12: 73.2 +/- 25.6; P < 0.001), plasma TGF-beta1 (basal: 11.2 +/- 5.9 vs. week 12: 4.89 +/- 2.25; P < 0.01) and urinary TGF-beta1 (basal: 18.12 +/- 9.27 vs. week 12: 10.32 +/- 2.0; P < 0.01) levels.
CONCLUSIONS: In patients with Type 1 diabetes, smoking increased oxidative stress, evaluated by lipid peroxidation, and TGF-beta1 production. Smoking cessation decreased these parameters, providing additional support to encourage diabetic patients to give up smoking.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008841     DOI: 10.1111/j.1464-5491.2004.01133.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

Review 1.  Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

Authors:  Tracy A McGowan; Yanqing Zhu; Kumar Sharma
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

2.  Smoking in diabetic nephropathy: sparks in the fuel tank?

Authors:  Vishal Arvind Chakkarwar
Journal:  World J Diabetes       Date:  2012-12-15

3.  Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers.

Authors:  Douglas Oliveri; Qiwei Liang; Mohamadi Sarkar
Journal:  Nicotine Tob Res       Date:  2020-06-12       Impact factor: 4.244

4.  Influence of smoking on levels of urinary 8-iso Prostaglandin F2α.

Authors:  Angela van der Plas; Sandrine Pouly; Guillaume de La Bourdonnaye; Gizelle Baker; Frank Lüdicke
Journal:  Toxicol Rep       Date:  2018-11-20

5.  Statistical analysis plan for "A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using a tobacco heating product on health effect indicators in healthy subjects".

Authors:  Oscar M Camacho; Andrew Hedge; Frazer Lowe; Nik Newland; Nathan Gale; Mike McEwan; Christopher Proctor
Journal:  Contemp Clin Trials Commun       Date:  2020-01-28

6.  Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite.

Authors:  Peter Boor; Sandra Casper; Peter Celec; Marta Hurbánková; Milan Beno; August Heidland; Kerstin Amann; Katarína Sebeková
Journal:  J Cell Mol Med       Date:  2008-10-06       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.